Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma has bolstered its financial standing through the successful completion of an $8 million financing round, alongside advancing its EB103 therapy into the Phase II segment of its ongoing Phase I/II trial, indicating significant progress in its clinical development. The encouraging independent Data and Safety Monitoring Board recommendation to proceed with Phase II trials acts as a pivotal marker for the company, potentially leading to broader patient recruitment and essential data on safety and efficacy. Furthermore, the innovative Artemis Technology platform not only provides a novel approach to CAR-T therapies but also opens new market opportunities in immunology and the treatment of solid tumors, enhancing the company's strategic position as it explores additional partnerships and extends its operational capabilities.

Bears say

Estrella Immunopharma's financial outlook appears negative due to concerns regarding potential stock dilution, particularly as management prepares to discuss strategic priorities and updates at the upcoming annual shareholders meeting. The company's target price has been significantly reduced from $16.0 to $8.0, reflecting a conservative approach amid uncertainties in pipeline development. Additionally, although the market opportunities for CD19 and CD22-targeted therapies appear promising, the declining stock price raises questions about the company's ability to sustain investor confidence and fund its ongoing clinical programs.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.